Baharia Mograbi

Dr. Baharia Mograbi


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2008 in Autophagy
Verified
Journal Article
Closed access
DKDaniel J. Klionsky
Daniel J. Klionsky
HAHagai Abeliovich
Hagai Abeliovich
PAPatrizia Agostinis
Patrizia Agostinis
DADevendra K Agrawal
Devendra K Agrawal
GAGjumrakch Aliev
Gjumrakch Aliev
RDRussell L Deter
Russell L Deter
(2008). Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy: Vol. 4, No. 2, pp. 151-175.

30 January 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PBPatrick Brest
Patrick Brest
PLPierre Lapaquette
Pierre Lapaquette
MSMouloud Souidi
Mouloud Souidi
KLKevin Lebrigand
Kevin Lebrigand
ACAnnabelle Cesaro
Annabelle Cesaro
Paul HofmanPaul Hofman
Paul Hofman

1 June 2016 in Cancer Cell
Verified
Journal Article
Closed access
MCMichael CEREZO
Michael CEREZO
ALAbdelali Lehraiki
Abdelali Lehraiki
AMAntoine Millet
Antoine Millet
FRFlorian Rouaud
Florian Rouaud
MPMagali Plaisant
Magali Plaisant
SRStephane Rocchi
Stephane Rocchi

8 January 2007 in Autophagy
Verified
Journal Article
Closed access
ECElisabeth Corcelle
Elisabeth Corcelle
NDNadir Djerbi
Nadir Djerbi
MMMireille Mari
Mireille Mari
MNMarielle Nebout
Marielle Nebout
CFCéline Fiorini
Céline Fiorini
BMBaharia Mograbi
Baharia Mograbi
Macroautophagy (hereafter referred to as autophagy) is the major degradative pathway of long-lived proteins and organelles that fulfils key functions in cell survival, tissue remodeling and tumor s...

1 July 2006 in Cancer Research
Verified
Journal Article
Open access
PDF file
ECElisabeth Corcelle
Elisabeth Corcelle
MNMarielle Nebout
Marielle Nebout
SBSoumeya Bekri
Soumeya Bekri
NGNils Gauthier
Nils Gauthier
Paul HofmanPaul Hofman
Paul Hofman
BMBaharia Mograbi
Baharia Mograbi
Helicobacter pylori infection of the human stomach causes chronic gastritis that can lead to gastric cancer. Because activated lymphocytes persist in the gastric mucosa, and because a high multiplicity of infection (MOI) of H. pylori is needed to induce apoptosis in vitro, we speculated that resistance of lymphocytes to apoptosis is an important feature of the immune response to H. pylori. Freshly isolated mouse splenocytes underwent substantial spontaneous apoptosis and displayed a biphasic response to H. pylori, in which low MOI (1-10) markedly inhibited apoptosis, whereas high MOI (≥75) potentiated apoptosis. Low MOI reduced mitochondrial membrane depolarization, caspase-3 and caspase-9 activation, and cytochrome c release and increased Bcl-2 levels. Low MOI also induced cellular proliferation. When cells were subjected to fluorescence-activated cell sorting after coculture with H. pylori, CD19+ B cells were found to be protected from apoptosis and undergoing proliferation at low MOI, whereas CD3+ T cells did not exhibit this pattern. The protective effect of low MOI on apoptosis persisted even when B cells were isolated before activation. Immunophenotyping showed that all B-cell subsets examined were protected from apoptosis at low MOI. Additionally, gastric infection with H. pylori resulted in protection of splenic B cells from spontaneous apoptosis. Our results suggest that the low levels of H. pylori infection that occur in vivo are associated with B-cell survival and proliferation, consistent with their potential to evolve into mucosa-associated lymphoid tissue lymphoma. (Cancer Res 2006; 66(13): 6834-42)

11 May 2010 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MIM İlie
M İlie
NMN M Mazure
N M Mazure
VHVéronique Hofman
Véronique Hofman
RAR E Ammadi
R E Ammadi
COC Ortholan
C Ortholan
Paul HofmanPaul Hofman
Paul Hofman
Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with non-small cell lung cancer (NSCLC). Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. The plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. The CAIX tissue immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome. CAIX tissue overexpression correlated with shorter overall survival (OS) (P=0.05) and disease-specific survival (DSS) of patients (P=0.002). The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals (P<0.001). A high level of CAIX in the plasma of patients was associated with shorter OS (P<0.001) and DSS (P<0.001), mostly in early stage I+II NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression (P=0.002) was a factor of poor prognosis in patients with resectable NSCLC. In addition, a high CAIX plasma level was an independent variable predicting poor OS (P<0.001) in patients with NSCLC. High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an independent prognostic biomarker in patients with NSCLC, in particular in early-stage I+II carcinomas.